Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.
Medtronic nets FDA nod for smart insulin pen app
Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Medtronic received Food and Drug
November 22, 2024